Years of planning behind the SARS-CoV-19 pandemic
It has been confirmed that Mr. Miles Guo tore up a significant document, named <13579>, during the press conference held in Washington on Oct 5, 2017. Each number has special meaning. “3” means that the Chinese Communist Party will create bioweapons in three years, starts from 2017, which can attack destructively in the United States. In the meantime, those bioweapons have strike abilities continuously in 5 years.
— Lude Media, on August 22, 2020.
CCP is Chinese Communist Party. CCP ≠ Chinese People. CCP ≠ China
— The New Federal State of China
I. Before 2017
- 2001 Great Opening — WTO
- 2001-2009 Bait — CROs
- 2009-2011 Going deep — Healthcare Reform
- 2011-2014 Blackmail — Market Rectification
- 2015 Are you in?
II.2017— Engine’s on
III. 2020 — Is the Chinese Communist Party ready?
IV. Truth with blood
I. Before 2017
- 2001 Great Opening — WTO
On December 11, 2001, China, under the regime of Chinese Communist Party, joined the World Trade Organization (WTO). China is not only a country, but also a platform for the Chinese Communist Party to acquire a license to trade legally all over the world. This event can also be likened to a company’s legal business license or a mafia officially cleansed, but the legal entity is the 1.4 billion Chinese people who knew nothing about it.
At that time, the United States (President Clinton in office) was looking forward to China’s accession to the WTO, as recalled by a former U.S. government official who participated in the pre-accession negotiations: “join the club of nations well along the road to democracy”.
- 2001-2009 Bait — CROs
Since SARS of 2003, China’s booming development of domestic biotech R&D, local pharmaceutical companies, and medical researches, along with the rapid expansion of biopharmaceutical-related capital markets and CROs (Contract Research Organisations), has created a strong attraction for foreign capital and multinational pharmaceutical companies. Incidentally,
On April 19 of 2009, PwC released a market report, Investing in China’sPharmaceutical Industry, both in English and Chinese. Even though all words are shining like gold, for me, a practitioner in pharmaceuticals, feels thrilling and finds their anti-human ambitions.
In Chapter 4 of this report, Contract Research Organisations Benefit From Pharma Moving Up the Value Chain, it listed a number of factors contribute to China’s increasing attractiveness on pharmaceutical industry:
- Cost and time savings. This is mainly reflected in cheap labor and low laboratory set-up costs. Overall, the cost of conducting clinical trials in China is only 30% of what it is in developed countries, with the savings pointing to quality checks and administrative costs. The time advantage will be shown in the next section.
- Patient pool. China’s large population base and the large number of people who have little or no access to medical care for certain diseases make it easier and less expensive to recruit patients for clinical trials.
- Animal resources. A significant amount of canines and primates used for animal testing in the US are already imported from China. By transferring the trials to China, Western companies can save on transportation and quarantine expense costs.
- Rapid Economic Growth. With the rapid growth of the pharmaceutical market, China is gradually becoming an important base for the future pharmaceutical market. This is mainly due to the growing affluence of the Chinese population and the corresponding increase in the number of people suffering from diabetes, cancer and cardiovascular diseases. This indicates that “there is great potential for drug development for the Chinese market”.
How many R&D facilities were there in China in 2009? Hundreds of R&D outsourcing organisations, mainly in large cities such as Beijing, Shanghai and Guangzhou. “an increasing number of domestic CROs emerge as one-stop service providers with the capability of providing all service offerings along the value chain, from drug discovery to registration and marketing”. Among the local R&D outsourcing companies, WuXi AppTec (listed on the New York Stock Exchange in 2007) is the leading domestic company in CROs area. Before 09, local R&D outsourcing companies began to expand abroad through acquisitions or partnerships. MNCs set up their own research centres and bases in China through direct or indirect partnerships or through the formation of joint ventures. I once asked a founder of a non-biopharmaceutical company who had been working in the Chinese pharmaceutical sector for over twenty years. According to his description, clinical reports for domestic drugs are usually given directly to medical universities or hospitals for experiments, and he had heard of several R&D outsourcing clinical institutions or R&D outsourcing companies in China. Although the names of these companies (such as WuXi AppTec) are familiar and they are known for their size and military background. “It’s certainly possible that it could be the universities and hospitals I’ve worked with that subcontract my orders to these organisations, I just don’t know about it”, he said. It appears that the R&D outsourcing business is not directly to domestic drug clinical services, and from their business actions are mainly focused on biopharmaceuticals.
- 2009-2011 Going deep — Healthcare Reform
During 2009 to 2011, Healthcare Reform was the major theme in China, which happened at the same time with Obamacare. What is healthcare reform all about? On Baidu search, there are 35,500,000 items yielded for the words “healthcare reform”. The implementation methods and actual operation of the local governments are even more diverse and strange. So how do we understand this “healthcare reform”? Is it really what it says, serving the people?
On December 21, 2012, the Boston Consulting Group (BCG) published an article on its website titled, Pharma’s Next-Billion Patients: Impact of Health Care Reform in China, 2009-2011. This article defined the goal of the health care reform as “the 400 million urban unemployed and the more than 650 million inhabitants of rural areas” and mentions that “about 96% of China’s population has public health-care insurance” and that “China’s pharmaceutical market is expected to grow in the future”” Not surprisingly, it may continue to expand over the years.” Since these one billion people have been covered by health insurance, these one billion people have become a billion lab rats for sale.
BCG published another article, Building a world-class, innovative therapeutic biologics industry in China, on February 6, 2013. It opens with a description of China’s potential to create a world-class biologics innovation segment, given timely policy announcements and implementation. “As China aims to develop the biologics industry, three questions need to be answered: 1. Are there lessons to be learned from the development of China’s small-molecule pharmaceutical and early-generation biologics sectors? 2. How quickly can China catch up with leading countries in terms of breakthrough innovation? 3. Can China’s largely unmet medical needs be translated into a meaningful market that can attract talent and economic activity and serve Chinese patients’ needs?” Biopharmaceuticals, speed, mass potential clinical trial enrolment and large demand, I guess sharks have already smelled the blood.
In January 2014, the Boston Consulting Group (BCG) has released a market report on the Chinese pharmaceutical market – New Rules for Winning in China’s Pharmaceutical Market. This report details five major changes to the Chinese pharmaceutical market following the healthcare reform:
- The establishment of Essential-Drug List (EDL). “Greater use of essential medicines in hospitals above the second level through policy requirements”. The EDL should “include more outstanding foreign medicines varieties”.
- The proportion of total drug revenue to total hospital revenue is strictly controlled through administrative means; accordingly, hospitals adjust the choice of drugs prescribed by doctors.
- A “diversified health insurance system” to increase the types of health insurance. The distribution channels and structure of drugs can be adjusted through health insurance.
- “The importance of compliance”, as the CCP has administratively corrected the “unfair competition” in the medical sector.
- CCP has introduced Good Management of Product (GMP), a GMP standard imported from the USA, but GMPs certified in China are not recognised by any developed country in the world; if you want to export, you have to have a new local inspection test in the country of entry) and requires all pharmaceutical companies to be certified by 2015. The government is also encouraging the adoption of GMP standards by the industry. In addition, “the government encourages industry consolidation to build larger local leading pharmaceutical companies, especially large state-owned pharmaceutical companies to lead the consolidation and restructuring of China’s pharmaceutical industry”.
That was the “advancement of the state and the retreat of the people”, which was so hotly debated in the healthcare industry during the time. It is not as simple as that based on where we are currently. All the companies that have grown in this healthcare reform have a role to play more or less in the current CCP Virus. The healthcare reform, so to speak, is a way of manipulating the industry structures and cutting off industries and areas that are not related to the main line of business, while removing people and interest groups that are not in bed with CCP. This main line is, of course, the <13579> that Lude Media exploded in the foreword. And, of course, through this healthcare reform, Chinese market and the “next-billion patients” will be a grand feast presented by CCP to multinational pharmaceutical companies all around the world.
- 2011-2014 Blackmail — Market Rectification
In July of 2013, GSK (short for GlaxoSmithKline) China Scandal happened. During that time, panic was widespread in the industry. There are several versions of the account of the incident, from which I have selected two for your perusal:
- Wikipedia: In 2013, the Chinese government announced that since 2007, GSK had provided HK$3.8 billion in kickbacks to GSK managers, doctors, hospitals and other prescribing entities through more than 700 travel agencies and consulting firms. Chinese authorities arrested four GSK executives as part of a four-month investigation, and in 2014 a Chinese court (coordinates unknown) found the company guilty of bribery and fined it $490 million. Mark Reilly, then head of GlaxoSmithKline’s UK headquarters in China, was sentenced to three years’ probation after a day-long, secret trial. Mark Reilly has reportedly been expelled from China and dismissed from the company.
- Baidu Baike: A bribery incident in the drug industry broke out in July 2013. The main manufacturer involved in the incident, GlaxoSmithKline, used bribery to seek an unfair competitive environment, resulting in rising prices in the pharmaceutical industry. Some executives of GlaxoSmithKline Investment Company Limited (GSK China) are under investigation for serious commercial bribery and other economic crimes. On May 15, 2014, after more than 10 months of investigation, GlaxoSmithKline (China) Investment Co. The GlaxoSmithKline (GSK) China bribery scandal took a turn for the worse on Sunday, June 30, 2014. The company said its executives received a secretly filmed sex tape featuring Mark Reilly, the company’s former head of China. GlaxoSmithKline confirmed that the video was shot in the bedroom of Mark Reilly’s apartment in Shanghai and featured him and his Chinese girlfriend. Mark Reilly had no knowledge of a secret camera in the bedroom. The tape reached company executives, including chief executive Sir. Andrew Witty, by anonymous email. The emails also claim the company paid kickbacks to doctors and officials for drugs.
Despite different kinds of speculation and interpretation spreading widely, and the intricacies of the case, one outcome is not controversial: many doctors in China were afraid to prescribe GlaxoSmithKline drugs after this scandal; “GlaxoSmithKline’s hospital promotions have been suspended for a long time,” said a company pharmaceutical representative; and Q3 2013 report showed, core business (prescription drugs and vaccines) sales in China plummeted 61%. After bribery scandal, rumours were swirling that GlaxoSmithKline would exit the Chinese market.
Sanofi, the world’s pharmaceutical titan, has been reported by a whistleblower in the industry in November 2007, 503 doctors from 79 hospitals in Beijing, Shanghai, Guangdong and Hangzhou received 1.69 million yuan (= $260,000 roughly) from the company’s “research expenses”. In addition, Sanofi also provided 43 doctors in five other hospitals in Beijing with more than 20,000 yuan of monthly benefits through cash reimbursement and gifts. The whistleblower, who keeps throwing bombshells to the outside world, always avoids his identity. According to the core information in its possession, Sanofi’s former employees believe that this whistleblower may be or at least used to be a senior employee of Sanofi China.
Around 2013, multinational pharmaceutical companies had been notified by the Chinese authorities for bribery, kickbacks, etc.. In the meantime, executives of those organisations had been investigated or even arrested for sex scandals and secret sex tapes. Those companies on the list are: Pfizer, Johnson & Johnson, Siemens, Novartis, Eli Lilly, Schweppes, Mead Johnson, SciClone, AstraZeneca, etc.. Even though the case had been closed, the fine had been paid, and the executives had been replaced after those scandals, the main medias, no matter domestic or foreign ones, will bring their scandals up from time to time.
CCP coerces all the players in the pharmaceutical industry, both national and multinational ones, to follow their patterns by market rectification and build an eco system on their own goals. And this market rectification is a process of domestication manipulated by CCP.
- 2015 Are you in?
In the first half of 2015, Bill Gates had a tight schedule of promoting the future of pandemics and investing in healthcare in different venues and interviews. The most famous of these events was that his speech on TED talk of April 2015, which could have been completely mistaken for taking place in the present day if it hadn’t been dated.
Bill Gates began his speech this way, “Today the greatest risk of global catastrophe doesn’t look like this. Instead, it looks like this (A 3D model of a coronavirus that looks exactly like SARS-CoV-19 today appears on the big screen)”. Indeed, CCP was focused on researching nuclear weapons until the 1980s; after the 1980s, it was as if nuclear weapons were left behind and they suddenly turned to economic development. It is noteworthy that many multinational pharmaceutical companies concentrated their entry into China in the 1980s.
There was also a lot of information in the presentation that was highly consistent with the course of today’s epidemic, such as the source of the virus and the economic loss, which was horrifying.
Starting from 05:04 of that speech, Bill Gates said, “… In fact, we can build a really good response system. We have the benefits of all the science and technology that we talk about here. We’ve got cell phones to get information from the public and get information out to them. We have satellite maps where we can see where people are and where they’re moving. We have advances in biology that should dramatically change the turnaround time to look at a pathogen and be able to make drugs and vaccines that fit that pathogen. So we can have tools, but those tools need to be put into an overall global health system. And we need preparedness. The best lessons, I think, on how to get prepared are again, what we do for war. For soldiers, we have full-time, waiting to go. We have reserves that can scale us up to large numbers… So those are the kinds of things we need to deal with an epidemic.” In his speech, he mentioned that there are five key pieces need to be prepared:
- Need to build strong health systems in poor countries; vaccines for kids;
- Need a medical reserve corps; lots of people who’ve got the training and background, who are ready to go, with the expertise.
- Need to to pair those medical people with the military; taking advantage of the military’s ability to move fast, do logistics and secure areas.
- Need to do simulations, germ games…so that we see where the holes are.
- Need lots of advanced R&D in areas of vaccines and diagnostics.
Recently, Bill Gates was interviewed by CNN and compared the current situation of COVID-19 with his prediction on TED five years ago. “When I did the forecast in 2015, I talked about the deaths potentially being higher. So this fires could be more fatal than it is. We didn’t get the worst case. But the thing that surprised me is that the economic impact in the US and around the world has been much greater than all the forecasts that I made 5 years ago”. He must be proud of his “smart and predictive” investment in healthcare industries, especially in China.
Four years before this “prophet-like” conference, there was an American thriller film, Contagion, released in 2011. The plot is a foreigner who traveled to China on a business trip and died after being infected with a mysterious and deadly virus in a casino in Macau. After that, the virus spread across the world, and public health crisis and humanitarian crises broke out all over the world. At the end of this film, in a flashback to the spillover event, a bulldozer razes palm trees while clearing a rainforest in China, disturbing some bats’ natural habitat. One bat finds shelter in a pig farm and drops an infected piece of banana, which is eaten by a pig. The pig is slaughtered and prepared by a chef in a Macau casino, who transmits the virus to Beth via a handshake. This film is a perfect trailer for today’s pandemic.
It is worthy of attention that there are two general scientific advisors to the film, one of them is W. Ian Lipkin, an epidemiologist at the Columbia Beijing Center of Columbia University’s Mailman School of Public Health, a special advisor to the Chinese Communist Party’s Ministry of Science and Technology on SARS in 2003, a winner of the International Science and Technology Cooperation Award from the Chinese Ministry of Science and Technology in 2016, a participant in the parade for the 70th anniversary of the founding of the Chinese Communist Party., and the world’s most renowned “virus hunter”.
This professor has a very high reputation in the actions against epidemics in China, such as SARS in 2003. At the beginning of the new coronavirus outbreak in 2020, on 28 January, he met with Professor Zhong Nanshan, an academician of the Chinese Academy of Engineering, to discuss the COVID-19 outbreak. On 1st of March, he was interviewed by Ms Yang Lan, a well-known Chinese female journalist and also a red sparrow of Chinese Communist Party, which went very well.
After all, do you buy their selling stories?
II. 2017 — Engine’s on
It is weird that all the pharmaceutical corporations on earth have rushed into one direction, biopharmaceuticals, since the 2000s (if there is a specific year, I would like to say 2001). What happened after all these market movements and structure manipulations? We can understand in this way that CCP incorporates those organizations into their communist troops and drives this chariot full of demons headed towards the darkness of human civilization.
On 10 October 2017, the China Food and Drug Administration (rebranded as the National Medical Products Administration, NMPA, in 2018) issued General Administration Order No. 35 “Decision of the State Food and Drug Administration on Adjusting Matters Relating to the Administration of Registration of Imported Medicines”.
In this Order, the requirements for the registration and management of imported drugs were adjusted:
- Prior to 2017, overseas drugs needed to go through clinical phase II or III before they could enter China; after this Decision, overseas drugs are allowed to undergo simultaneous phase I clinical trials in China; and, there is an exception for biological products (but the content of the exception is not specified).
- After completing the clinical trial in China, the applicant can apply for marketing registration of the drug directly in China.
- “For new chemical drugs and therapeutic biologics for which applications for clinical trials of imported drugs and applications for marketing of imported drugs are submitted, the requirement that the marketing permission of the country or region where the overseas pharmaceutical manufacturer is located should be obtained is abolished” In my humble opinion: if a clinical trial is not approved in other countries out of China, for example, US, there is no restriction to do it in China. A green light.
- “For those registration applications, which have been accepted before the release of this Decision, exemptions of imported drugs clinical trials proposing the international multi-centre clinical trial data, they can be directly approved for import if they are in line with the Drug Registration Management Measures and related documents requirements.” In China, the only way you can have an exemption is that you are one of them(CCP).
How far does this Order go? Olivier Brandicourt, Chief Executive Officer of Sanofi at the time, delivered a keynote speech at the 2019 International Pharmaceutical Innovation Forum held on March 26th. Mr. Brandicourt welcomed China’s recent policies and healthcare reforms. “From 2000 to 2016, the Chinese authorities approved around 100 medicines…Just this past year(2018), the NMPA approved 48 medicines, close to the annual standards of the European Medicines Agency or the US FDA. More importantly, behind these figures, there are millions of Chinese patients who now have access to the most innovative medicines in therapeutic areas like oncology, rare diseases and infectious diseases,” he said.
After 2017, major multinational pharmaceutical companies have been investing more in the Chinese market. For example:
- In August 2017, GSK and Alibaba Health (AliHealth) jointly created a strategic partnership project “Rui Zhi – Adult Vaccine Service System” (“Rui Zhi Project”) to officially launch. “Project Rui Zhi is just the beginning of an innovative collaboration between the two companies, which provides information on cervical cancer vaccination. In the future, GSK Vaccines China and Ali Health will also cooperate more in children’s vaccines and other adult vaccines, providing users with a series of O2O services such as disease prevention knowledge popularisation, online answers from doctors and offline vaccination consultation appointments”.
- In July 2018, Sanofi established its Global R&D Operations Hub in Chengdu, Sichuan Province, to focus on R&D digitalisation and big data analytics. It makes China into its third pillar of global clinical development and operations, after France and the United States.
III. 2020 — Is Chinese Communist Party ready?
On 9 June 2019, millions of people in Hong Kong protested on the streets against the Extradition Law Amendment Bill, which attracted worldwide attention and I wonder if it caught the CCP off guard. According to the plan of ‘13579’, CCP needs to form the capability to attack the US within 3 years. So with 2020 still to come, can CCP’s ‘13579’ still go ahead as usual?
In the wake of the Hong Kong Anti-Extradition Law Amendment Bill Movement in June 2019, two things have happened:
On 6 June 2019, Olivier Brandicourt, former CEO of Sanofi, announced his resignation, citing his desire to retire. However, on 6 November 2015, Sanofi announced its 2015-2020 strategic roadmap and its ambition to become the pre-eminent diversified global healthcare company. For reaching those goals, Sanofi reshaped its portfolio, expected accelerated sales growth in 2018 and projected total annual R&D investments of more than €6 billion in 2020. In support of this strategic plan, in May 2016, Brandicourt announced a reorganisation of the company’s management. It would appear that the “retirement” of Olivier Brandicourt was not planned.
Following his ‘retirement’, Paul Hudson took over as CEO on 1 September. The new Chief Executive Officer, who has no medical background and comes from a sales background, was previously CEO of Novartis. However, the promotion of Paul Hudson’s taking office was released after October. Needless to say, the handover from predecessor to incumbent felt a little rushed. So where is Olivier Brandicourt going? According to “internal rumour” from Sanofi, Brandicourt did not leave Sanofi, but went to a lab specialising in RNAi research under Sanofi. However, instead of finding this lab, Olivier Brandicourt’s name was found on the board of directors of Alnylam Pharmaceuticals Inc. in February 2020. What is this Alnylam? It is a biopharmaceutical company founded in 2002 and based in Cambridge, Massachusetts; dedicated to the development and commercialisation of RNA interference (RNAi) therapeutics for genetically defined diseases? In addition, Genzyme, a biopharmaceutical company based in Cambridge, Massachusetts, which Sanofi fully acquired in 2011, acquired a 12% stake in Alnylam in 2014. At the beginning of covid-19 pandemic, one of the treatment options recommended by CCP is the use of RNA interference therapeutics. What a coincidence!
Besides, It was surprised to find that Olivier Brandicourt is a member of the National Committee on United States-China Relations in New York, USA (date of membership unknown), of which Henry Kissinger is the executive vice chair.
In June 2019, Sanofi was not the only multinational pharmaceutical company to change its executives, but also other pharmaceutical companies in China, like Roche, Bayer, Bristol-Myers Squibb, GE Healthcare, etc.. There were 23 pharmaceutical companies across China have announced the departure of their executives since June; the reasons for resignation mainly include personal reasons, job changes, and having reached retirement age and leaving their positions.
On 10 June 2019, the CCP State Council issued executive order No. 717, Regulations of the People’s Republic of China on Human Genetic Resources Management. According to the information on the CCP’s government website, the regulation was “adopted at the 41st meeting of the Standing Committee of the State Council on 20 March 2019”, written on “28 May 2019″ and published on “10 June 2019” and then “came into force on 1 July 2019”.
The entire Regulation, so to speak, is extremely roughly worded, for example in the original text.
Chapter I, Article 10: Prohibition of trade in human genetic resources.
Legal provision for scientific research or use of human genetic resources and payment or charging of reasonable costs shall not be regarded as sale and purchase.
Chapter 2, Article 11: If a person collects human genetic resources from important genetic families or specific regions in China, or collects human genetic resources of the type or quantity specified by the administrative department of science and technology under the State Council, the following conditions shall be met and approved by the administrative department of science and technology under the State Council: (a) having legal personality; (b) having a clear and legitimate purpose of collection; (c) having a reasonable collection plan; (d) having passed ethical examination; (e) having a department and management system in charge of human genetic resources management; (f) having premises, facilities, equipment and personnel appropriate to the collection activities.
It can be seen that the genetic markets or the markets related to genetic resources are no longer a multiplayer game in China. It has become a solo game, dominated by the Chinese Communist Party.
In the service matters of the government service platform of the Ministry of Science and Technology of the CCP, there is an item in the service guide of human genetic resources management about the filing of international collaborative clinical trials of human genetic resources in China. There are several points that caught the author’s attention: 1. no limit on the number of genetic resources to be applied for; 2. applicant requirements: Chinese units with legal personality; 3. no need for a text of informed consent; no need to submit a study protocol; 4. a list of participating medical institutions and project leaders is attached. Here, I would like to revert to this report from PwC’s, Investing in China Pharmaceutical Industry in 09. The R&D outsourcing organisations mentioned therein can be explained here. To some extent, the whole CROs industry are state-owned by Chinese Communist Party. I guess that the role of these CROs is to take orders of clinical trials from abroad and then outsource them twice or more to hospitals and medical institutions all over China, especially covering countless private hospitals and small clinics scattered throughout various secondary counties and cities, which served the poorest 900 million people in the country.
Among numerous global market reports and market assessments on antibody therapeutics, part of the genetic data is provided from Chinese sources, and some even directly from the “China Government”. It is hard to imagine a dictatorial regime has engaged so deeply into healthcare research and development for decades of years.
IV. Truth with blood
“The tree of liberty must be refreshed from time to time with the blood of patriots and tyrants.”
— Thomas Jefferson
On October 5 2017, Mr. Miles Guo hold a conference in Washington D.C. to state confidential documents from Chinese Communist Party (CCP) and tried to warn American people that the darkness from CCP was arriving at USA. On Jan 19 2020, Lude Media exposed the truth of SARS-CoV-19, of which the confidential materials came from Dr. Li-Meng Yan. Since that, the Whistleblower Movement and the New Federal State of China continually spread the truth to people who love peace and want to protect their family all around the world by GTV and G|News. In April, Dr. Li-Meng Yan escaped from Hong Kong under CCP’s surveillance with the help of the Rule of Law Foundation. During this rescue, at least 20 people had been captured, even disappeared, by CCP’s military police. On July 10 2020, It was the first time Dr. Li-Meng Yan showed up in public after arriving in the USA. She was interviewed by Fox News and she accused CCP’s cover-up of COVID-19 pandemic in December of 2019. In the following months, Dr. Li-Meng Yan published two scientific reports on zenodo.org. In these two important reports, she proved that SARS-CoV-2, which caused the global epidemics and the death of more than one million people worldwide, must have been a product of laboratory modification and it is an Unrestricted Bioweapon created by a laboratory of the People’s Liberation Army (PLA).
It is worth noting that the top secret of CCP, <13579>, mentioned by Mr. Guo who was interviewed by Steven Bannon’s War Room on September 5 2020, revealed that CCP planned over several years to wage a bioterrorism on US soil and attempted to disrupt the US Election for controlling the United States. How to make it happen? It is obvious that CCP has turned China into virus manufacturing chains and built a virus eco to serve their ambitions. It is easy to explain their patterns, according to Chinese martial hero fictions, that the bad guys have both poisons and antidotes most of the time.